A Randomized Double Blind Placebo Control Study of Huang-Chi-Wu-Wu- Tang in Patients With Intracranial Arterial Stenosis
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01553643|
Recruitment Status : Unknown
Verified March 2012 by China Medical University Hospital.
Recruitment status was: Recruiting
First Posted : March 14, 2012
Last Update Posted : March 14, 2012
Intracranial arterial prominent stenosis (IAPS) is one of main cause of stroke especially in Asia. Although antiplatelet aggregative or anticoagulant agent and even surgical operation are used to treat patients with IAPS, the incidence of stroke occurrence still remains high. In addition, symptomatic IAPS most common cause continuous deterioration, thus, increase the incidence of stroke. Therefore, there is a good method to reduce the inceidence of stroke that is to prevent the progressive deterioration of IAPS.
Huang-Chi-Wu-Wu-Tang is made of Astrgalus membranaceus (Fisch.) Gge , Paeonia lactiflora Pall , Cinnamom Twig , Zingiber officinale Rose , Ziziphus jujube Mill , and can treat hemiplegia in the traditional Chinese medicine writings. Astragaloside IV is a component of Astrgalus membranaceus, may reduce th cerebral infarction area in middle cerebral arterial occlusion mice. The investigators previous studies have known that paeoniflorin that a component of Paeonia lactiflora Pall can decrease the cerebral infarction area and neurological deficit in middle cerebral arterial occlusion rats. Therefore, the purpose of the present study was to investigate the effect of Huang-Chi-Wu-Wu-Tang on patients with IAPS.
|Condition or disease||Intervention/treatment||Phase|
|Intracranial Arterial Stenosis||Drug: Chinese Herb Huang-Chi-Wu-Wu-Tang Drug: placebo||Phase 4|
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||80 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|
|Study Start Date :||January 2010|
|Estimated Primary Completion Date :||November 2012|
|Experimental: Chinese Herb Huang-Chi-Wu-Wu-Tang||
Drug: Chinese Herb Huang-Chi-Wu-Wu-Tang
Huang-Chi-Wu-Wu-Tang at a rate of 3g two times per day
|Placebo Comparator: Placebo||
at a rate of 3g two times per day
- Primary outcome measure was the improvement hemodynamics at intracranial vessels in the M1 segment of middle cerebral artery (MCA) or basilar artery (BA) shown in transcranial color-coded sonography (TCCS). [ Time Frame: 3 years(all patients) ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01553643
|Contact: Chung Hsiang Liu, MD.||886-4-22052121 ext email@example.com|
|China Medical University Hospital||Recruiting|
|Contact: Chung Hsiang Liu, MD.|
|Principal Investigator:||Chung Hsiang Liu, MD.||China Medical University Hospital|